Page 4 - Dr Reddys

Sensex ends 134 pts lower, Nifty settles at 11,505; Nifty Pharma jumps 5%

All that happened in the markets today

BSE Healthcare index hits record high; Laurus Labs, Dr Reddy's at new highs

Lupin, Stride Pharma, Neuland Labs, Lincoln Pharma, and Hikal hit their respective 52-week highs on the BSE

Russia ropes in Dr Reddy's to sell 100 mn Covid-19 vaccine doses; stk up 4%

Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India, Dr Reddy's said in a statement

New launches, patents: Multiple catalysts for Dr Reddy's US business

The ongoing pace of product launches in the US should lead to stronger growth after a good Q1, say analysts

Cipla tweaks management structure to mobilise second level of executives

Do these changes augur well for the future business growth plans? Analysts think so

TCS, Infosys, and Dr Reddy's shares hit fresh record highs

Dr Reddy's rallied 5 per cent to Rs 4,524 today, surging 12 per cent in the past two trading days after the company reported a strong operational performance in Q1FY21.

India's coronavirus drug market set for price war as firms ready launches

Sources say Cipla-BDR's favipiravir will be at least 30 per cent cheaper than Glenmark's price of Rs 103 per tablet. Cipla did not confirm.

Covid-19 crisis: Made-in-India remdesivir may come by end of June

Currently, the drug is allowed for "restricted emergency use" on severely ill hospitalised Covid patients in India.

Revised Wockhardt deal boosts prospects of Dr Reddy's India business

The company, according to its new strategy, is focusing on growing its India-based branded products

Dr Reddy's Q4 PBT up 22% at Rs 714 cr on buoyant US, European business

The company has registered 10% growth in revenues at Rs 4,431.8 cr for the quarter under review from Rs 4,016.6 cr in the year-ago period

Dr Reddy's gets USFDA inspection closure report fo Srikakulam unit

The plant is one of the company's three units that were served a warning letter in November 2015 for not following the prescribed operational and manufacturing quality standards

Dr Reddy's Labs hits over 4-year high, surges 62% from March low

Analysts believe Dr Reddy's US business, which has been facing revenue pressure, is likely to rebound with new product launches and the gradual normalization of price erosion in its key products.

Dr Reddy's board approves borrowing of Rs 2,000 cr through multiple routes

DRL's board also the approved sale of the Contract Development and Manufacturing Organisation(CDMO) division of Custom Pharmaceutical Services (CPS), on a slump sale basis

USFDA seeks voluntary action at Dr Reddy's Andhra Pradesh facility

Shares of Dr Reddy's Laboratories on Friday closed 0.55 per cent down on the BSE

Diabetes to be our focus in India, US: Wockhardt's Habil Khorakiwala

Wockhardt is present in emerging markets like Mexico, Brazil with insulins

New launches, regulatory go-ahead key triggers for Dr Reddy's

Sales in the US, its biggest market, accounting for 37 per cent of revenues, were up 8 per cent year-on-year (YoY) and 12 per cent sequentially, led by five new launches

Top headlines: Air India's 100% stake sale; 1,000 frauds in 5 years at UCBs

From government announcing a 100 per cent stake sale in Air India to a new case of Coronavirus in India here are today's top headlines

Stock recommendation from Prabhudas Lilladher: Buy Dr Reddy's, GAIL

The stock of Dr. Reddy's has been on a gradual rise with positive indicators supporting the momentum and currently has given a breakout above the previous peak of 3,000

Dr Reddy's falls 5% as rival firm beats Co to US FDA approval for EluRyng

Rival firm Amneal Pharma has received approval for generic birth-control product NuvaRing from the US Food and Drug Administration.

Technical calls by Religare Broking: Buy Dr Reddy's Lab, Ramco Cements

Weekly Technical Recommendations by Religare Broking Ltd.